PATENT CLAIM ANALYSIS

Application Number: 16229821
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "04400A"]

Abstract:
The. invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with an antisense molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such antisense molecule used in said method.

Claim (Index 16):
An antisense oligonucleotide of 25 nucleotides in length, wherein the antisense oligonucleotide comprises at least 18 consecutive bases of a base sequence of the sequence CUGUUGCCUCCGGUUCUGAAGGUG (SEQ ID NO: 115), in which uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino phosphorodiamidate antisense oligonucleotide, and wherein the antisense oligonucleotide induces exon 53 skipping of human dystrophin pre-mRNA.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.46939
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14542183', '13094548', '14631686', '14859598', '12992218']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7888230739373311
- 35 USC 102 Novelty (BERT): 0.584763085813595
- Combined Prediction Score: 0.7684170751249575
- Mean Citation Score: 354.87618000000015
- Max Citation Score: 375.91483
- Similarity Product: 286.2512563964927

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test